Background: Bone is an uncommon site of metastasis in patients with advanced hepatocellular carcinoma (HCC). Therefore,there are few studies concerning the natural history of bone metastasis in patients with HCC.Patients and Methods: Data on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for211 deceased HCC patients with evidence of bone metastasis were statistically analyzed.Results: The median age was 70 years; 172 patients were male (81.5%). The median overall survival was 19 months. Themedian time to the onset of bone metastasis was 13 months (22.2% at HCC diagnosis); 64.9% patients had multiple bonemetastases. Spine was the most common site of bone metastasis (59.7%). Most of these lesions were osteolytic (82.4%);88.5% of them were treated with zoledronic acid. At multivariate analysis, only the Child Score was significantly correlatedwith a shorter time to diagnosis of bone metastases (p = 0.001, HR = 1.819). The median survival from bone metastasis was 7months. At multivariate analysis, HCC etiology (p = 0.005), ECOG performance status (p = 0.002) and treatment withbisphosphonate (p = 0.024) were associated with shorter survival after bone disease occurrence. The site of bone metastasisbut not the number of bone lesions was associated with the survival from first skeletal related event (SRE) (p = 0.021) and OS(p = 0.001).Conclusions: This study provides a significant improvement in the understanding the natural history of skeletal disease inHCC patients. An early and appropriate management of these patients is dramatically needed in order to avoid subsequentworsening of their quality of life.
|Numero di pagine||13|
|Stato di pubblicazione||Published - 2014|